Patents
Literature
4094 results about "Binding protein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A binding protein is any protein that acts as an agent to bind two or more molecules together. Examples include: DNA-binding protein Single-strand binding protein Telomere-binding protein RNA-binding protein Poly-binding protein Nuclear cap-binding protein complex CREB-binding protein Calcium-binding protein Calcium-binding protein 1 S100 calcium-binding protein A1 TATA-binding protein Actin-binding protein Penicillin binding proteins Retinol binding protein Retinol binding protein 4 EP300 Binding immunoglobulin protein Odorant binding protein Lipopolysaccharide-binding protein C4b-binding protein Rap GTP-binding protein Calmodulin-binding proteins Iron-binding proteins Thyroxine-binding proteins Folate-binding protein Sterol regulatory element-binding protein GTP-binding protein Retinaldehyde-binding protein 1 Ccaat-enhancer-binding proteins Androgen-binding protein Maltose-binding protein Phosphatidylethanolamine binding protein 1 Syntaxin binding protein 3 Insulin-like growth factor-binding protein Methyl-CpG-binding domain protein 2 Growth hormone-binding protein Vitamin D-binding protein Syntaxin binding protein 2 Oxysterol-binding protein E3 binding protein
Methods and compositions for modulating SHP2
PCT designated stage expiredWO2025019666A1Organic active ingredientsOrganic chemistryDiseasePharmaceutical drug
Disclosed herein are compounds having the Formula I: SHP-L-Hs (I) and pharmaceutically acceptable salts thereof, wherein SHP is a chemical entity that binds to SHP2 protein, L is a linker, and Hs is chemical entity that binds HSP90 protein. Pharmaceutical compositions comprising the disclosed compounds and their uses for treating diseases responsive to modulation of SHP2 protein are also provided.
Owner:RANOK THERAPEUTICS (HANGZHOU) CO LTD +7
Methods of using Anti-SP17 immunotherapeutics
ActiveUS20250011460A1Microbiological testing/measurementBiological material analysisSperm proteinAntiendomysial antibodies
This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.
Owner:MEDICOVESTOR INC
Nucleic acids, vectors, and cells that encode Anti-SP17 antibodies and other SP17 binding proteins
ActiveUS20250011403A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsSperm proteinAntiendomysial antibodies
This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.
Owner:MEDICOVESTOR INC
Monoclonal antibody or antigen binding fragment thereof for detecting folic acid and binding protein complex thereof, preparation method and application thereof
The invention relates to a monoclonal antibody for detecting folic acid and a binding protein complex thereof or an antigen binding fragment thereof, and a preparation method and application thereof, the monoclonal antibody or the antigen binding fragment thereof comprises: (1) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3, HCDR1, HCDR2 and HCDR3, and (2) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO.3; the light chain variable region is provided with an LCDR1, an LCDR2 and an LCDR3, and the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 are respectively shown as SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6. The monoclonal antibody or the antigen binding fragment thereof can bind folic acid and a protein compound thereof with high specificity and high affinity, so that the detection accuracy and sensitivity of folic acid are improved, the limitation that a traditional competition method detection reagent is low in sensitivity and poor in clinical correlation is broken through, and sandwich method immunodetection of folic acid is realized.
Owner:NANJING OKAY BIOTECHNOLOGY CO LTD +1
Methods of using anti-SP17 immunotherapeutics
ActiveUS12319747B2Microbiological testing/measurementBiological material analysisSperm proteinTherapeutic antibody
This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.
Owner:MEDICOVESTOR INC
Analysis of antigen-binding proteins
PCT designated stage expiredWO2025022002A1BiostatisticsSequence analysisAntigen bindingBioinformatics
A method for predicting one or more features of an antigen-binding protein is provided, comprising: providing the amino acid sequence of at least part of one or more chains of the antigen-binding protein or an encoded sequence derived therefrom as input to a deep learning model comprising a sequence encoding module configured to take as input an amino acid sequence and to produce as output an embedding corresponding to the input sequence, and predicting the one or more features of the antigen-binding protein using the embedding produced by the sequence encoding module The sequence encoding module has been trained as part of a machine learning model comprising a structure encoding module, and using training sequence data and structure data from a plurality of antigen-binding proteins. Related methods, systems and products are also described.
Owner:ALCHEMAB THERAPEUTICS LTD
Ligand discovery and gene delivery via retroviral surface display
ActiveUS12222347B2Tumor rejection antigen precursorsAntibody mimetics/scaffoldsGene deliveryBinding domain
Compositions of retroviruses and methods of using the same for gene delivery are disclosed, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.
Owner:MASSACHUSETTS INST OF TECH
TL1a binding antibodies and methods of use
PCT designated stage expiredWO2025038473A1AntipyreticAnalgesicsAntiendomysial antibodiesAntigen binding
Owner:PARAGON THERAPEUTICS INC
Proteins that bind SP17 including fully-human Anti-SP17 antibodies
ActiveUS20250011420A1Immunoglobulins against cell receptors/antigens/surface-determinantsPharmaceutical non-active ingredientsSperm proteinAntiendomysial antibodies
This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.
Owner:MEDICOVESTOR INC
α4β7 integrin binding proteins and methods of use
PCT designated stage expiredWO2025038708A1AntipyreticAnalgesicsAntiendomysial antibodiesCell biology
Owner:PARAGON THERAPEUTICS INC
Kit and detection method for detecting tomato brown crinkled fruit virus based on enzyme-mediated dual-amplification nucleic acid amplification
PendingCN120210426AMicrobiological testing/measurementDNA/RNA fragmentationEnzyme systemSingle strand
The invention discloses a kit for detecting tomato brown crinkled fruit virus based on enzyme-mediated dual-amplification nucleic acid amplification and a detection method. The detection system comprises a primer pair DNA (deoxyribonucleic acid) upstream primer (F5) and a DNA downstream primer (R6) for amplifying the tomato brown crinkled fruit virus movement protein gene, a probe (RNA primer (RNA1)) for detecting the MP gene, a nucleic acid amplification group enzyme system (recombinase, single-chain binding protein, polymerase and ATP (adenosine triphosphate) energy regeneration enzyme), a signal amplification group enzyme system (positioning enzyme and cutting enzyme), activating enzyme NTP, a buffer solution and RNase-free Water. The system composed of the freeze-drying protective agent is prepared into the pre-subpackaged freeze-dried balls. The kit disclosed by the invention can realize DNA detection of aM concentration, and besides rapid qualitative detection of the tomato brown crinkled fruit virus, early screening of the tomato brown crinkled fruit virus can also be realized due to high detection sensitivity.
Owner:SUZHOU JINGRUI BIOTECHNOLOGY CO LTD +2
Il-23 antibody compositions and methods of use
PCT designated stage expiredWO2024263900A2Immunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntiendomysial antibodiesProtide
Owner:PARAGON THERAPEUTICS INC
Anti-p-Tau217 protein monoclonal antibody as well as preparation method and application thereof
The invention provides a monoclonal antibody of a p-Tau217 protein and an application of the monoclonal antibody. In particular, the present invention provides an antibody or an antigen binding fragment thereof targeting a p-Tau217 protein. The antibody provided by the invention can specifically recognize and bind the p-Tau217 protein, does not recognize p-Tau181 and non-phosphorylated Tau protein, and can be used for preparing a detection preparation or a kit for diagnosing diseases related to the p-Tau217 protein, such as Alzheimer's disease.
Owner:SHANGHAI BIOGERM MEDICAL TECH CO LTD +1
Recombinant CD47 binding proteins and their use
PCT designated stage expiredWO2024251695A1Immunoglobulin superfamilyAntibody mimetics/scaffoldsDiseaseAnkyrin Repeat Protein
The present invention relates to recombinant binding proteins comprising a designed ankyrin repeat domain with binding specificity for CD47. In addition, the invention relates to nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such recombinant binding proteins or nucleic acids, and the use of such recombinant binding proteins, nucleic acids or pharmaceutical compositions in methods of treating diseases, such as cancer, in a mammal, including a human.
Owner:MOLECULAR PARTNERS AG
Test strip for rapidly detecting methicillin-resistant staphylococcus aureus and application of test strip
The invention provides a test strip for rapidly detecting methicillin-resistant staphylococcus aureus and application of the test strip, and belongs to the technical field of biochemical detection. The test strip comprises a bottom plate, a sample pad, a combination pad, a detection pad and a water absorption pad, the two ends of the detection pad are in lap joint with the combination pad and the water absorption pad respectively, the detection pad is located on the lower portion, the sample pad is in lap joint with the combination pad, and the combination pad is located on the lower portion; a detection line and a quality control line are arranged on the detection pad, the detection line is arranged on one side close to the combination pad, and the quality control line is arranged on one side close to the water absorption pad; the detection pad is coated with a MoS2 nanosheet, the combination pad is coated with a penicillin binding protein 2a polyclonal antibody labeled by horse radish peroxidase, and the detection line is coated with a penicillin binding protein 2a monoclonal antibody; the quality control line is coated with goat anti-rabbit IgG (immunoglobulin G). The kit is high in sensitivity and wide in linear range, has good specificity, repeatability and stability, and can effectively detect MRSA in a clinical sample.
Owner:CHONGQING NO 3 PEOPLES HOSPITAL
DNA binding protein and RNA binding protein classification method based on ESM-2 and dual-path neural network
ActiveCN119229982Aproportional balancequality improvementBiostatisticsBiological modelsA-DNANucleic acid binding protein
The invention provides a DNA binding protein and RNA binding protein classification method based on ESM-2 and a dual-path neural network, and particularly relates to a staged classification method combining the ESM-2 and the dual-path neural network, which is called DRBP-EDP. In the first stage training, the protein sequence is classified as a nucleic acid binding protein or a non-nucleic acid binding protein; further classifying the nucleic acid binding protein as a DNA binding protein or an RNA binding protein in the second stage of training; meanwhile, a fine data set construction method is further constructed, so that a high-quality protein classification data set is created, through the method, the DRBP-EDP model obtains good performance, the classification accuracy of the nucleic acid binding protein and the non-nucleic acid binding protein in the first stage is 90.03%, and the classification accuracy of the non-nucleic acid binding protein in the second stage is 90.03%. In the second stage, the classification accuracy of the DNA binding protein and the RNA binding protein is 89.56%, a new insight and a new method are provided for protein classification, an innovative tool is provided for research on protein functions, and therefore a new opportunity is provided for development of life science.
Owner:SANYA NATIONAL INSTITUTE OF SOUTHERN BREEDING CHINESE ACADEMY OF AGRICULTURAL SCIENCES +1
CDH17 antibodies and methods of treating cancer
PendingCN119212721ABiological material analysisAntibody ingredientsPharmaceutical drugAntigen binding
The present disclosure provides antigen binding proteins that bind to CDH17; a bispecific antigen binding protein that binds to CDH17 and a second antigen; and conjugates thereof. Also provided herein are related polypeptides, nucleic acids, vectors, host cells, and conjugates. In addition, kits and pharmaceutical compositions comprising these entities are also provided. Methods of making the antigen binding proteins and methods of treating subjects having cancer are also provided.
Owner:RGT UNIV OF CALIFORNIA
Recombinant CD16a binding proteins and their use
PCT designated stage expiredWO2024251628A1Peptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAnkyrin Repeat ProteinAnkyrin
The present invention relates to recombinant binding proteins comprising an ankyrin repeat domain, wherein the ankyrin repeat domain has binding specificity for CD16a. In addition, the invention relates to nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer in a mammal, including a human.
Owner:MOLECULAR PARTNERS AG
A nucleic acid aptamer binding to CD117 protein and its application
PendingCN119752914AOrganic active ingredientsCell receptors/surface-antigens/surface-determinantsAptamerAbnormal expression
The present invention discloses a nucleic acid aptamer binding to CD117 protein and its application, wherein the nucleic acid aptamer has a nucleotide sequence that has at least 60% homology with any one of SEQ ID NO.1 to SEQ ID NO.2 and binds to CD117 protein. The nucleic acid aptamer of the present invention has a small molecular weight, stable structure and chemical properties, is easy to store and label, is easy to modify, and can be artificially synthesized in a short period of time. The nucleic acid aptamer obtained by the present invention can be used for CD117 protein detection, purification or imaging, and can also be used to prepare drugs for diagnosis or treatment of abnormal expression of CD117 protein, such as purification to obtain high-sensitivity and high-specificity detection of CD117 protein, and has broad application prospects.
Owner:HANGZHOU INSTITUTE OF MEDICAL SCIENCES CHINESE ACADEMY OF SCIENCES
Processing method and device for protein mutation effect and electronic equipment
The invention relates to the cross technical field of artificial intelligence and biotechnology, and provides a protein mutation effect processing method and device and electronic equipment.The protein mutation effect processing method comprises the steps that an amino acid sequence of protein before mutation and an amino acid sequence of protein after mutation are obtained; performing feature extraction on the amino acid sequence of the protein before mutation and the amino acid sequence of the protein after mutation through a pre-trained protein language model to obtain features of the protein before mutation and features of the protein after mutation; determining protein mutation characteristics based on the characteristics of the protein before mutation and the characteristics of the protein after mutation; and inputting the protein mutation characteristics into a pre-trained first natural language model to generate text description corresponding to the protein mutation. According to the method, the interpretability of the protein mutation effect is improved by combining a protein language model and a natural language processing technology.
Owner:TSINGHUA UNIVERSITY +1
Base editing system based on TraC effect protein and application thereof
The invention belongs to the field of gene engineering, and relates to a DNA binding protein based on TraC effect protein, a fusion protein with a cytosine / adenine base editing function, an editing system and nucleic acid molecules or constructs for encoding the DNA binding protein and the fusion protein. The invention also relates to complexes and kits for gene editing comprising the fusion proteins of the invention or the nucleic acid molecules encoding them. The base editing tool disclosed by the invention can realize efficient, accurate and safe base editing in cells of various eukaryotes such as animals and plants. The unique characteristics of the base editing tool enrich the types of existing base editing tools, and the base editing tool has wide application prospects.
Owner:BEIJING QI BIODESIGN BIOTECHNOLOGY CO LTD
Protein binder search
A specification of a binding target protein is received. A machine learning model is used to predict a plurality of candidates for a property of a selected amino acid position of a binder protein to bind to the binding target protein. For each selected property candidate of the plurality of property candidates, the selected property candidate is used as a model input to predict properties for one or more other amino acid positions into a corresponding candidate set of properties. The corresponding candidate sets are evaluated using a binding quality evaluation. Based on the evaluation, one of the plurality of property candidates is selected as a determined result property of the selected amino acid position. The determined result property is used as a model input to predict a plurality of candidates for a property of a different selected amino acid position included in the binder protein.
Owner:CHAN ZUCKERBERG BIOHUB INC
DHODH polypeptide degradation agent and application thereof in preparation of medicine for preventing and / or treating DHODH-mediated diseases
ActiveCN120192429APolypeptide with localisation/targeting motifFusion with degradation motifDiseaseUbiquitin ligase
The invention provides a DHODH polypeptide degradation agent and application of the DHODH polypeptide degradation agent in preparation of drugs for preventing and / or treating DHODH-mediated diseases, and belongs to the technical field of biological medicines. The invention provides a DHODH polypeptide degradation agent. The DHODH polypeptide degradation agent comprises a cell-penetrating peptide, a DHODH binding peptide, a linker and an E3 ubiquitin ligase VHL binding peptide which are sequentially connected from an N terminal to a C terminal. The DHODH polypeptide degradation agent provided by the invention can be efficiently combined with DHODH protein, and has a good anti-tumor effect on the cellular level and the animal level. The compound has a good application prospect in preparation of drugs for preventing and treating DHODH-mediated diseases, overcomes the defects that existing drugs for treating DHODH-related diseases are single in variety and insufficient in curative effect, and has important significance.
Owner:EAST CHINA UNIV OF SCI & TECH +1
Application of rice BRW1 gene in regulation and control of grain weight character
ActiveCN120041469AClimate change adaptationMicrobiological testing/measurementBiotechnologyGrain weight
The invention belongs to the field of gene engineering, and relates to a rice BRW1 gene and application thereof. The cDNA (complementary deoxyribonucleic acid) sequence of the rice BRW1 gene is shown as SEQ ID NO.1, and the amino acid sequence of the RNA binding protein coded by the rice BRW1 gene is shown as SEQ ID NO.2. The invention discloses the rice RNA binding protein gene BRW1 and the protein coded by the rice RNA binding protein gene BRW1. The rice BRW1 gene controls the grain weight of grains, the thousand grain weight of a knockout mutant of the gene is remarkably increased, and meanwhile the grain length and the grain width are increased. By mutating the BRW1 gene in the invention, the grain weight of rice grains can be increased, which indicates that the genetic improvement of the grain weight and grain shape of rice is facilitated by using the gene.
Owner:NANJING AGRICULTURAL UNIVERSITY
Vaccine composition and application thereof
The present disclosure provides a vaccine composition wherein the antigen components comprise a factor H binding protein (fHbp), a recombinant outer membrane vesicle (OMV) carrying porin A (PorA protein), and optionally a heparin binding protein (NHBA protein). The antigen components in the vaccine composition disclosed by the invention have a good synergistic effect, so that the vaccine composition has extremely high vaccine forming potential, is used for preventing epidemic of group B meningococcus, and plays a role in protecting infection of group B meningococcus.
Owner:SINOVAC RES & DEV CO LTD
Albumin binding proteins and methods of use
Owner:PARAGON THERAPEUTICS INC
Nucleic acid aptamer combined with TIDG6 protein as well as application and screening method of nucleic acid aptamer
PendingCN119685320ARadioactive preparation carriersPharmaceutical non-active ingredientsAptamerRNA Sequence
The invention relates to the technical field of biology, in particular to a nucleic acid aptamer combined with TIDG6 protein, application and a screening method of the nucleic acid aptamer, and the nucleic acid aptamer has a nucleotide sequence as shown in SEQ ID NO.1; or a nucleotide sequence which has at least 30% homology with SEQ ID NO.1 and is combined with TIDG6 protein; the nucleic acid aptamer is an RNA sequence transcribed by a nucleotide sequence as shown in SEQ ID NO.1, or an RNA sequence transcribed by a nucleotide sequence as shown in SEQ ID NO.1. The nucleic acid aptamer is small in molecular weight, stable in chemical property, easy to store and mark, capable of being combined with TIDG6 protein with high affinity, very good in specificity, capable of being used in the aspects of detection, diagnosis, imaging, treatment and the like and wide in application prospect.
Owner:ZHEJIANG UNIV OF TECH +1
Dissociation agent and kit
PCT designated stage expiredWO2025087337A1Biological testingFluorescence/phosphorescenceProteasePathology
Disclosed in the present invention are a dissociation agent and a detection kit for thyroid function detection. The dissociation agent comprises a protease and a reducing agent, and can effectively dissociate the bound forms of T3 and T4 in serum from binding proteins to form a free state. The dissociation agent and kit of the present invention are used for fluorescent immunochromatography detection, so that signal interference can be effectively reduced, and the sensitivity and accuracy of the detection can be improved.
Owner:LEADWAY HK
Composition for detecting NAD < + > and application thereof
The invention specifically discloses a composition for detecting NAD < + > and application thereof, and relates to the technical field of biological detection. According to the composition for detecting NAD < + >, the composition comprises an NAD < + > binding protein fragment A connected with an Fc tag, an NAD < + > binding protein fragment B and a connecting peptide, the detection result is accurate and reliable, and meanwhile the technical difficulty, uncertainty and high cost faced by antibody screening in a traditional method are avoided.
Owner:HEFEI KNATURE BIO PHARM CO LTD
Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
ActiveUS12226424B2Organic chemistryPharmaceutical non-active ingredientsProtein targetChemical compound
The present disclosure relates to compounds of formula (I) and their anti-tumor uses, and their intermediates of formula (III), intermediates of formula (IV), and uses of the intermediates. The compound of formula (I) has a degrading effect on a specific target protein, which is mainly composed of three parts. The first part is a small molecule compound (SMBP, Small Molecules Binding Protein) that can bind to a protein, the second part LIN is a linker, and the three-part ULM is a ubiquitin ligand (ULM, Ubiquitin Ligase Binding Moiety), wherein SMBP is covalently bound to LIN, and LIN is covalently bound to ULM. A series of compounds designed and synthesized in the present disclosure have a wide range of pharmacological activities, including the functions of degrading specific proteins and / or inhibiting activities of specific proteins, and thus can be used in related tumor treatments.
Owner:SHANGHAI TECH UNIV